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Melissa A. Cadnapaphornchai*
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary 
kidney disease and is associated with concerning long-term implications for kidney 
function and cardiovascular health. Early intervention is needed in order to mitigate 
these long-term complications. Herein, we review important findings from recent clinical 
trials in ADPKD and their relevance to affected children and young adults and consider 
future directions for intervention. Recent clinical trials support aggressive control of blood 
pressure with blockade of the renin-angiotensin-aldosterone system as well as potential 
benefit of pravastatin therapy in children and young adults with ADPKD. There are several 
other candidate therapies, some of which have shown benefit in adult ADPKD, which 
require further investigation in affected children.
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Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney 
disease, affecting one in 500 individuals and accounting for nearly 5% of end-stage kidney disease 
in the United States (1). Although historically considered a disease of adults, it has become clear in 
recent decades that ADPKD can have significant clinical manifestations as early as in utero. Early 
intervention to mitigate progression of structural kidney disease is anticipated to have the most 
long-term impact on outcome. Thus, recent clinical trials have focused on early stage ADPKD and 
specifically on the potential benefits of intervention during childhood. The purpose of this article is 
to review important findings from recent clinical trials in children and young adults with ADPKD 
and to discuss future directions for therapeutic intervention.
LeSSONS LeARNeD FROM NATURAL HiSTORY  
STUDieS iN CHiLDReN
Observational studies in the 1980s and 1990s in children at risk for ADPKD (i.e., one parent known 
to have ADPKD) began to delineate the extent of disease in children and to identify specific risk 
factors for subsequent intervention (2, 3). Through such studies, we learned that children with 
ADPKD had larger kidneys which grew faster than those of unaffected children. Moreover, the 
larger the kidneys were at baseline imaging, the faster they grew over time. Ultrasonography was 
shown to be a reliable non-invasive tool for the diagnosis of ADPKD in children. Specifically with 
the degree of resolution available in the 1990s, this method could delineate kidney cysts in nearly 
80% of children aged 5–18 years with known PKD1 mutations (2). The presence of bilateral cysts in 
at-risk children is sufficient for diagnosis (4). Many of the same clinical manifestations, which had 
typified adult ADPKD, including pain, gross and/or microhematuria, proteinuria, and impaired 
urinary concentrating ability, were also present in affected children, with frequency of symptoms 
correlating to extent of structural kidney disease. Early cardiovascular disease was also of concern 
in the pediatric population, with a high prevalence of hypertension and elevated left ventricular 
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mass index (LVMI) as compared to unaffected children (5, 6). 
Distinct from adults, however, the vast majority of children with 
ADPKD maintained normal kidney function despite progressive 
structural kidney disease, thus emphasizing the great importance 
of total kidney volume (TKV) as a measureable outcome of early 
disease progression and the primary focus of therapeutic inter-
vention in the pediatric ADPKD population. Although there is 
good correlation between ultrasound and magnetic resonance 
imaging (MRI) assessment of TKV in ADPKD children (7), MRI 
is the preferred method to follow TKV in the research setting 
and clearly is a more accurate and reliable measure as structural 
disease advances (8).
BLOOD PReSSURe CONTROL iN ADPKD
Blood pressure control is a critical aspect of chronic kidney disease 
(CKD) management in both children and adults, with numerous 
studies showing delayed deterioration in kidney function with 
more aggressive control (9–11). The prevalence of hypertension 
in pediatric ADPKD is estimated to be 20% (12), with an even 
higher prevalence in very early onset ADPKD (13, 14). Previous 
studies in adults with ADPKD implicated a major role for the 
renin-angiotensin-aldosterone system (RAAS) in the pathogen-
esis of hypertension and left ventricular hypertrophy [reviewed 
in Ref. (15, 16)]. Although postulated, there has however been 
no direct evidence that RAAS induces kidney cyst growth in this 
condition.
With these considerations, an interventional trial was designed 
to assess the effect of aggressive control of blood pressure with 
angiotensin-converting enzyme inhibition (ACEI) on kidney 
and cardiovascular disease progression in children and young 
adults ages 4–21  years with ADPKD (17). Study participants 
with hypertension (blood pressure above the 95th percentile for 
height, sex, and age) were randomized to enalapril treatment with 
goal blood pressure at the 90th percentile (HBP90) or at the 50th 
percentile (HBP50), while participants with high normal blood 
pressure (75th–95th percentile for height, sex, and age) were 
randomized to either enalapril with goal blood pressure at the 
50th percentile (NBP50) or to observation without treatment 
(NBP90). All participants were followed annually for 5  years 
with routine laboratory testing, 24-h urine creatinine clearance 
as an estimate of glomerular filtration rate (eGFR), abdominal 
ultrasound and MRI assessment of TKV, and echocardiographic 
assessment of LVMI.
Not surprisingly, participants in the HBP50 group required 
more antihypertensive medications (mean ± SEM: 2.8 ± 0.3 vs. 
1.6 ± 0.4; P < 0.05) than HBP90 participants. Regardless of the 
degree of hypertension control, however, participants in both of 
these study groups demonstrated a significant increase in TKV 
and decrease in eGFR over the study period. No significant 
differences were observed in LVMI or urine albumin excretion 
between study groups or over time. These results emphasized the 
high risk for structural and functional kidney disease progression 
associated with hypertension in children with ADPKD.
The clinical trial further demonstrated that baseline LVMI in 
high normal blood pressure participants was similar to that of 
hypertensive participants and was elevated compared to those 
with blood pressure below the 75th percentile, suggesting that 
early cardiovascular involvement is present even with blood pres-
sure in the upper quartile of the normal range. Both NBP50 and 
NBP90 groups demonstrated a rise in TKV over time despite BP 
control with ACEI in the NBP50 group. However, participants in 
the NBP90 group demonstrated significant decrease in eGFR and 
increase in LVMI over the study period, while these parameters 
were stable in the NBP50 group. No significant difference was 
observed in urine albumin excretion between these study groups 
at baseline or over time. These findings suggested that children 
and young adults with ADPKD and high normal blood pressure 
may represent a particular subgroup for whom rigorous control 
of blood pressure with ACEI could confer renal functional and 
cardiovascular protection.
Limitations of this single-center pediatric research study 
include the relatively small number of participants as compared 
to adult trials despite nationwide recruitment, the restricted 
number of participants consistently achieving goal BP in the 
hypertensive group (40% in HBP50 vs. 70% in HBP90 while 
100% of NBP participants met BP goal), and the generous drop-
out rate (27% overall). The latter speaks to a common struggle 
associated with longitudinal clinical trials in the pediatric 
population (18, 19).
Subsequently, the multicenter HALT-PKD study was 
conducted (20). This double-blind, placebo-controlled trial 
included 558 hypertensive participants 15–49 years of age with 
early stage ADPKD (eGFR greater than 60  mL/min/1.73  m2) 
who were randomized to either a standard blood pressure 
target (120/70–130/80 mm Hg) or a low blood pressure target 
(95/60–110/75 mm Hg) and to either the ACEI lisinopril plus 
an angiotensin-receptor blocker (telmisartan) or to lisinopril 
plus placebo. Serial follow-up was performed for 5–8 years with 
a primary outcome of annual percentage change in TKV by 
MRI. The trial included a very limited number of participants 
in the pediatric age group, with mean age of study participants 
overall of 36 ± 8 years. Combined lisinopril/telmisartan did not 
significantly alter the rate of increase in TKV as compared to 
lisinopril/placebo. However, as compared with standard blood 
pressure control, rigorous blood pressure control was associ-
ated with a small (1.1% per year) but significant reduction in 
TKV and no change in eGFR. Not surprisingly, there was a 16% 
increase in dizziness and light headedness in the low blood 
pressure target group.
It is important to note that in the HALT-PKD study, there 
was no control arm without RAAS blockade. Thus the ability 
to assess the specific effect of RAAS blockade on TKV was 
limited. In addition, there were more participants in the low 
BP group with PKD2 mutations (19.8 vs. 13.1%); PKD2 is 
associated with less progressive kidney disease as compared 
to PKD1 (21). Finally, the percentage of subjects consistently 
meeting BP goal was limited. Specifically, the systolic and 
diastolic blood pressures, as measured at home, were on target 
across all study visits in 40–66 and 58–75% of participants in 
the low-blood pressure group, respectively, and in 32–48 and 
33–52% of those in the standard-blood pressure group, respec-
tively. These factors could each have affected the outcome of 
the clinical trial.
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The KDIGO Controversy Conference on ADPKD has sug-
gested a target blood pressure of less than 140/90 in adults with 
ADPKD with a stricter goal below 130/80 if macroalbuminuria 
is present (22) and further recommended management of hyper-
tension in ADPKD children per routine guidelines for the general 
pediatric population (goal below 90th percentile for age, sex, 
and height) (23) with RAAS blockade as the preferred first-line 
treatment for hypertension in ADPKD (22). Despite these rec-
ommendations, the above-described clinical trials intimate that 
more aggressive control of BP might be of value for both kidney 
and cardiovascular reasons in select ADPKD patients. Further 
investigations are needed to better characterize the long-term 
relevance of these observations.
Hyperkalemia and reduced GFR are unusual in pediatric 
ADPKD as kidney function is usually normal. However, the 
risk of fetal birth defects with RAAS blockade during pregnancy 
remains an important topic for discussion when providing such 
treatment to females of appropriate pubertal development.
STATiN THeRAPY iN PeDiATRiC ADPKD
HMG-CoA reductase inhibitors (statins) have been shown to 
enhance renal blood flow and GFR and to attenuate inflamma-
tion through vascular and glomerular nitric oxide production 
[reviewed in Ref. (24, 25)]. In an animal model of ADPKD, 
lovastatin reduced the severity of structural and functional 
kidney disease (26), and in a small study of ADPKD adults, 
short-term (4-week) treatment with simvastatin was associated 
with improved renal blood flow and GFR (27). Although the 
underlying mechanisms are not well understood, it has been 
proposed that these renoprotective effects are mediated by 
statin-related inhibition of G proteins, leading to decreased cell 
proliferation.
In this context, a 3-year randomized double-blind placebo-
controlled phase III clinical trial of pravastatin treatment on 
kidney and cardiovascular disease progression in children and 
young adults ages 8–22 years with ADPKD and normal kidney 
function was conducted (28). The primary outcome variable 
was a combined endpoint of ≥20% increase in TKV corrected 
for height (HtTKV), LVMI, or urine albumin excretion over the 
study period. All participants received ACEI treatment. Fewer 
participants receiving pravastatin achieved the primary endpoint 
compared with placebo (69 vs. 88%; P = 0.03) (29). This was due 
primarily to a lower proportion reaching the increase in HtTKV 
(46 vs. 68%; P = 0.03), with similar findings observed between 
study groups for LVMI (25 vs. 38%; P = 0.18) and urine albumin 
excretion (47 vs. 39%; P = 0.50). The percent change in HtTKV 
adjusted for age, sex, and hypertension status over the 3-year 
period was significantly decreased with pravastatin (23 ± 3% vs. 
31 ± 3%; P = 0.02). In mixed-model longitudinal data analysis, 
the increase in percent growth over 3  years was significantly 
different between the statin and placebo groups (P = 0.01). The 
medication was well tolerated with no adverse effects on serum 
liver or muscle enzymes; no participant discontinued pravastatin 
due to side effects.
The mechanisms of statin effect on kidney cyst growth remain 
to be fully elucidated. Mass spectrometry-based analysis of 
biomarkers of endothelial dysfunction, inflammation, and oxida-
tive stress was pursued in this cohort (30). Pravastatin therapy 
was associated with reduced plasma concentrations of cyclooxy-
genase- and lipoxygenase-derived plasma lipid mediators (e.g., 
9-hydroxyoctadecadienoic acid, 13-hydroxyoctadecadienoic 
acid, and 15-hydroxyeicosatetraenoic acid) over the course of the 
research study as compared to placebo. These metabolites have 
been previously shown to enhance the profibrotic effects of angio-
tensin II (31) and to activate the peroxisome proliferator-activated 
receptor γ, which has been implicated in cyst growth (32). Thus 
reduction via statin therapy would be anticipated to be of benefit 
in ADPKD.
These findings support the use of pravastatin to ameliorate 
progressive structural kidney disease in children and young 
adults with ADPKD. Whether statin therapy may be beneficial 
in earlier childhood (i.e., prior to 8  years of age) or in more 
advanced ADPKD as in older adults is not currently known and 
requires study. With a readily available, well-tolerated medication 
which can mitigate progression of kidney disease in children with 
ADPKD, however, issues now arise regarding whether/when to 
screen at-risk children. A thoughtful discussion with families 
regarding the potential benefits and risks of diagnosis (including 
potential impact on future life/disability insurance) and implica-
tions of treatment on long-term prognosis is necessary. Early 
intervention remains critical in order to have the most long-term 
impact on kidney and cardiovascular outcomes (33–35). As with 
ACEI, potential risks to the fetus with statin exposure during 
pregnancy should be reviewed as appropriate prior to treatment.
CLiNiCAL TRiALS iN ADULTS wiTH 
ADPKD AND iMPLiCATiONS FOR 
PeDiATRiC ADPKD
Results from other recent clinical trials in adults with ADPKD 
must also be considered, recognizing as always that findings 
from adult studies are not necessarily generalizable to the 
pediatric population. In 1989, Grantham et  al. reported that 
in human kidney ADPKD cells (but not normal kidney cells), 
vasopressin-induced cyclic 3′,5′-adenosine monophosphate 
(cAMP) stimulated chloride-driven fluid secretion, and B-Raf/
Mek/extracellular signal-regulated pathway cell proliferation 
and dedifferentiation, implicating cAMP as an important regu-
lator of growth in ADPKD kidney cysts (36, 37). Some years 
later, Gattone et al. demonstrated an impressive decrease in cyst 
fluid accumulation via blockade of the vasopressin V2 receptor 
in rat and mouse models of polycystic kidney disease (38, 39). 
Subsequently, the multicenter international TEMPO 3:4 study 
included nearly 1,500 adults (aged 18–50  years) with ADPKD, 
eGFR above 60  mL/min/1.73m2, and relatively large kidneys 
(TKV > 750 mL) who were randomized to vasopressin V2 recep-
tor blockade with tolvaptan or to placebo for 3  years (40, 41). 
All participants were advised to avoid thirst by drinking a glass 
of water after each urination. Participants in the tolvaptan arm 
demonstrated slower annual increase in TKV than controls (2.8 
vs. 5.5%; P < 0.001) and slower annual decline in kidney function 
(−2.6 vs. −3.8 mg/mL; P < 0.001). Suppression of plasma arginine 
vasopressin (AVP) concentration was observed in both groups, 
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likely due to voluntary water intake by placebo participants. Thus 
the observed magnitude of effect between treatment and placebo 
groups may have been diminished. It is important to note that 
the TEMPO clinical trial included participants with relatively 
advanced disease (TKV > 750 mL) and thus the potential benefit 
to the general ADPKD population may be overestimated based 
on trial results. It is further unknown if the effect on TKV and 
renal functional decline would be sustained with ongoing treat-
ment beyond a 3-year period.
Based on these clinical trial results, tolvaptan was subsequently 
approved for rapidly progressive ADPKD in adults in Europe, 
Japan, Korea, and Canada but not in the United States. There is 
nevertheless some variability regarding the definition of “rapid 
progression” and thus which patients merit therapy. Although it 
has been proposed that tolvaptan could decrease annualized TKV 
growth by 1.99% per year (P < 0.001) and eGFR decline by 0.40 
(P = 0.23) in CKD stage 1 (42), for example, European guidelines 
have recommended against starting tolvaptan in patients aged 
30–40  years with CKD stage 1 (eGFR >  90  mL/min/1.73  m2) 
due to slow progression of disease (43). The U.S. Food & Drug 
Administration denied the new drug application for tolvaptan for 
ADPKD in 2013, citing concern for side effects (including sig-
nificant liver enzyme elevation in 4.4%) and high study dropout 
rate (23 vs. 14%) in the TEMPO trial. Of note, two participants 
met definition for Hy’s Law case although all cases resolved with 
drug withdrawal. Despite the positive results of the TEMPO trial, 
concern also remains regarding the cost-effectiveness of tolvaptan 
for ADPKD, with a recent Markov-based analysis suggesting that 
while tolvaptan therapy could prolong median age at end-stage 
kidney disease by 6.5 years, this came at a cost of $744,100 per 
quality-adjusted life-year gained (44).
With the positive results of the TEMPO trial, there is great 
interest to apply tolvaptan to pediatric ADPKD. Several con-
siderations are needed however in planning such a pediatric 
trial. The severity of structural kidney disease as studied in the 
TEMPO trial (TKV >  750  mL) is not as common among the 
general pediatric ADPKD population. Thus, the effect of therapy 
may be less impressive than in the TEMPO trial, and there are 
significant potential side effects as detailed above. Furthermore, 
the vast majority of children with ADPKD maintain normal renal 
function (CKD stage 1), and a validated method to identify slow 
vs. rapid progressors does not exist in the pediatric population. 
Therefore, patient selection criteria must be carefully delineated. 
Finally, the lower age limit at which children can be expected 
to appropriately compensate for vaptan-induced polyuria has 
not been well established. These and other concerns have led 
to delay in initiation of a pediatric ADPKD clinical trial with 
tolvaptan although future carefully designed studies should be 
forthcoming.
It has been proposed that modulation of kidney cyst growth 
similar to V2 receptor blockade might be achieved easily and 
safely with suppression of AVP via chronic high fluid intake (45). 
Such an intervention is attractive for use in the pediatric age 
group due to its low risk of potential side effects. The feasibility of 
inducing low urine osmolality has been demonstrated in a small 
pilot study in ADPKD adults (46). Thirty-four participants ages 
18–60 years with ADPKD and eGFR ≥ 60 mL/min/1.73 m2 were 
randomly assigned to a low-osmolar diet vs. no intervention for a 
2-week period. The intervention group demonstrated a significant 
decrease in urine osmolality and mean plasma copeptin levels, a 
marker of AVP effect, over the study period. However, a small 
non-randomized clinical trial of high fluid intake for 1 year in 
adults with ADPKD was paradoxically associated with increased 
TKV (47). It remains to be determined whether constant high 
fluid intake on a prolonged basis is truly practicable in either 
adults or children, the latter whom may have some difficulty 
consistently following a low-osmolar diet with protein needs for 
growth, and thereafter what effect these interventions might have 
on kidney cyst growth long term.
Somatostatin analogs such as octreotide and lanreotide have 
been utilized in adults with ADPKD to impact both polycystic 
liver and polycystic kidney disease. These medications inhibit 
cAMP production through stimulation of Gαi. The ALADIN 
study demonstrated diminished growth in TKV after 1 year of 
treatment with octreotide but the effect was not sustained after 
3 years (48, 49). An observational study of 6-month treatment 
with lanreotide in adults with polycystic liver/kidney disease 
demonstrated a slight but statistically significant decrease in 
median TKV (1,023–1,012 mL; P =  0.006) (50). Further study 
is needed to determine whether there is a sustained clinically 
significant effect of these medications on TKV in ADPKD. Such 
medications may have a more important role in management 
of PKD-associated polycystic liver disease, which would be an 
exceedingly rare occurrence in childhood ADPKD.
Inhibitors of the mammalian target of rapamycin (mTOR) 
have been previously studied in adult ADPKD. The mTOR 
pathway plays an important role in cell growth and prolifera-
tion, including interaction of the cytoplasmic tail of polycystin 
1 with tuberin. Inappropriate activation has been observed in 
some cyst-lining epithelial cells in human ADPKD patients and 
in mouse models of ADPKD (51, 52). Animal studies suggested 
that rapamycin, an inhibitor of mTOR, reduced cystogenesis, an 
effect which is dependent on appropriate blood levels and the 
tubular origin of cyst development (52, 53). Such studies led to 
subsequent clinical trials of mTOR inhibition in adult ADPKD 
with disappointing results. Sirolimus treatment had no effect on 
TKV or kidney function over an 18-month period in adults with 
ADPKD and normal kidney function (54). Gastrointestinal side 
effects of sirolimus were common, with 82% of treated partici-
pants complaining of mucositis. Everolimus treatment for 2 years 
in adults with ADPKD resulted in a non-significant slower rate 
of increase in TKV and faster decline in eGFR (55). Cytopenias 
and mucositis occurred significantly more frequently in the treat-
ment group. These medications have not been studied in pediatric 
ADPKD, but their use is likely to be limited by the high rate of side 
effects and concern for possible deleterious effects of long-term 
immunosuppression beginning early in life.
An alternative approach for suppressing mTOR activity is to 
utilize agents that activate AMP-activated kinase (AMPK). This 
kinase has been shown to antagonize mTOR activation (56). In 
this regard, metformin, a pharmacological activator of AMPK, 
has been demonstrated to arrest cyst growth in mouse models 
of PKD (57). Metformin has the advantage of being extensively 
utilized in clinical and research settings in a variety of medical 
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conditions including diabetes and polycystic ovary syndrome in 
both adults and children. Thus, ample safety data are available 
for review. The medication is also relatively inexpensive and may 
have anti-inflammatory and anti-fibrotic effects [reviewed in Ref. 
(58)], which could be of potential benefit for vascular health in 
ADPKD. Clinical trials are currently ongoing to assess the effect 
of metformin on kidney cyst growth and function in adults 
with ADPKD (NCT02903511, NCT02656017). With increasing 
experience with metformin in children with various medical 
conditions, metformin represents a candidate intervention for 
children with ADPKD which requires further reflection.
Curcumin, from the plant curcuma longa, is a naturally 
occurring polyphenol found in the spice turmeric, which has 
the unique ability to activate transcription of key antioxidants, 
suppress inflammation, and reduce cell proliferation, leading 
to recent application in conditions of abnormal cell growth 
including cancer. In various animal models of acute and chronic 
kidney injury, curcumin treatment has been shown to mitigate 
renal injury (59–61), possibly by reduced activation of the pro-
inflammatory transcription factor NFκB and its downstream 
target tumor necrosis factor-α (TNF-α), concomitant with an 
increase in the anti-inflammatory transcription factor peroxisome 
proliferator-activated receptor-γ (PPARγ) (62, 63). Curcumin has 
been shown to slow cyst growth in vitro in a dose-response man-
ner, using both the Madin–Darby canine kidney cell cyst model 
and an embryonic kidney cyst model (64). These effects appear at 
least in part to be mediated by alteration in intracellular signaling 
proteins like Ras, B-raf, p-MEK, p-ERK, c-fos, and Egr-1. In the 
Pkd-1 deletion mouse model, curcumin improves renal histol-
ogy and reduces proliferative index, cystic index, and kidney 
weight normalized to total body weight (65). Curcumin has also 
been shown to reduce vascular dysfunction in rodent models of 
hypertension, diabetes, and aging (66–69). These improvements 
are associated with increased vascular nitric oxide bioavailability 
and arterial eNOS expression, reduced vascular oxidative stress 
(decreased reactive oxygen species, reduced oxidative damage, 
and increased antioxidant enzymes), and increased activity of 
hemoxygenase-1, which can promote anti-inflammatory path-
ways (66–69). Vascular dysfunction is known to occur in adults 
with ADPKD (70), and cardiovascular disease is the leading cause 
of mortality in ADPKD (71). Recent studies have shown that chil-
dren and young adults with ADPKD also have vascular dysfunc-
tion as evidenced by impaired endothelial dependent dilation and 
increased arterial stiffness (72) as compared to healthy children. 
The results of such studies formed the rationale for a randomized 
placebo-controlled interventional trial of curcumin therapy in 
children and young adults with ADPKD (NCT02494141), which 
is currently ongoing. This study will assess brachial artery flow-
mediated dilation and aortic pulse wave velocity at baseline and 
following 12 months of curcumin vs. placebo. Secondary outcome 
measures include height-corrected TKV as well as various urine 
and plasma markers of inflammation and oxidative stress.
CONCLUSiON
Autosomal dominant polycystic kidney disease is a common 
kidney condition with major implications for long-term health. 
Structural kidney disease and vascular dysfunction are evident 
in childhood, and the earlier we can mitigate these processes, 
the more favorable the long-term renal and cardiovascular 
prognoses. It is critical to establish a reliable means to identify 
children at highest risk for rapid progression and to design safe 
interventional trials which can be initiated in childhood. Several 
previously investigated and potential therapeutic interventions 
have been reviewed here and their relevance to the pediatric 
ADPKD population discussed. Recent clinical trials suggest ben-
efits of aggressive control of blood pressure with RAAS blockade 
as well as statin therapy in affected children. Tolvaptan shows 
great promise to mitigate structural and functional kidney disease 
progression in adults with advanced ADPKD, but cautious study 
is needed in affected children. The mechanisms of cyst forma-
tion are quite complex. Thus, it seems likely that a combination 
of treatments will be necessary to optimally inhibit cyst growth 
and that the ideal combination of therapies may vary over time 
relative to disease stage in both children and adults.
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